2024
Introducing the JAMA Summit
Bibbins-Domingo K, Angus D, Park H, Lewis R, Khera R, Zeis J, Flanagin A, Curfman G. Introducing the JAMA Summit. JAMA 2024, 331: 1451-1451. DOI: 10.1001/jama.2024.5570.Commentaries, Editorials and LettersArtificial IntelligenceCongresses as TopicDelivery of Health CareHumansInterdisciplinary CommunicationPeriodicals as TopicRandomized Controlled Trials as TopicUnited States
2019
Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia
Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A. Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia. American Journal Of Clinical Oncology 2019, 42: 270-274. PMID: 30628912, DOI: 10.1097/coc.0000000000000514.Peer-Reviewed Original ResearchMeSH KeywordsDietHumansInfection ControlInfectionsNeoplasmsNeutropeniaPrognosisRandomized Controlled Trials as TopicConceptsRate of infectionUnrestricted diet groupNeutropenic dietAcute lymphoblastic leukemiaCancer patientsAcute myeloid leukemiaDiet groupInfection rateUnrestricted dietNeutropenic cancer patientsPrimary outcome measureLower patient satisfactionRisk of infectionRandom-effects modelingComprehensive database searchDatabase inceptionLymphoblastic leukemiaPatient satisfactionRestrictive dietsMyeloid leukemiaRelative riskSTUDY SELECTIONOutcome measuresPRISMA guidelinesPatients
2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Obesity AgentsBayes TheoremBenzazepinesDrug CombinationsFemaleFructoseHumansLactonesLiraglutideMaleMiddle AgedNaltrexoneObesityOrlistatPhentermineRandomized Controlled Trials as TopicTopiramateWeight LossConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants
2014
“Inflammation and arterial stiffness in humans”
Jain S, Khera R, Corrales–Medina V, Townsend RR, Chirinos JA. “Inflammation and arterial stiffness in humans”. Atherosclerosis 2014, 237: 381-390. PMID: 25463062, DOI: 10.1016/j.atherosclerosis.2014.09.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory AgentsBiomarkersCardiovascular DiseasesHumansInflammationRandomized Controlled Trials as TopicRisk FactorsVascular StiffnessConceptsPrimary inflammatory diseaseArterial stiffnessArterial stiffeningInflammatory diseasesPrimary inflammatory conditionsAnti-inflammatory interventionsRole of inflammationAnti-inflammatory therapyEffect of statinsEffects of inflammationPotential therapeutic targetCardiovascular morbiditySubclinical inflammationInflammatory conditionsGeneral populationTherapeutic targetInflammationEstablished markerNormal adultsPotential mechanismsDiseaseHypertensionMorbidityStatinsArtery